Method of manufacturing a medicated porous metal prosthesis
First Claim
Patent Images
1. A method of manufacturing a stent for providing local delivery of a therapeutic agent at an implantation site, comprising:
- sintering metallic fibers into a sintered stent material having a plurality of porous holding cavities open to one side;
forming the sintered stent material into a stent; and
loading a therapeutic agent into the cavities of the stent prior to implanting the stent at the implantation site.
1 Assignment
0 Petitions
Accused Products
Abstract
A method of manufacturing a medicated prosthesis such as a stent. The method includes forming a stent out of porous metal and loading a therapeutic agent into the pores of the metal. In one embodiment the stent is formed from a sintered metal wire, sheet, or tube and can include adding a coating to the stent. When the stent is implanted into the vasculature of a patient, the therapeutic agent in the stent dissipates into the tissue of the vasculature proximate the stent.
769 Citations
38 Claims
-
1. A method of manufacturing a stent for providing local delivery of a therapeutic agent at an implantation site, comprising:
-
sintering metallic fibers into a sintered stent material having a plurality of porous holding cavities open to one side;
forming the sintered stent material into a stent; and
loading a therapeutic agent into the cavities of the stent prior to implanting the stent at the implantation site. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)
the sintered stent material comprises a sheet; and
the forming step includes chemical etching the sheet into the form of an expandable stent.
-
-
5. The method of claim 2, wherein the metallic fibers are woven into a sheet prior to said sintering step.
-
6. The method of claim 1, wherein:
-
the sintered stent material comprises a sheet; and
the forming step includes cutting the sheet with a laser into the form of a stent.
-
-
7. The method of claim 5, wherein the metallic fibers are woven into a sheet prior to said sintering step.
-
8. The method of claim 1, wherein said sintered stent material comprises a porous metal wire.
-
9. The method of claim 1, further comprising the step of weaving the metallic fibers into a sheet.
-
10. The method of claim 2, wherein the stent is emersed for a period of time sufficient to permit a therapeutic agent to be absorbed into the porous cavities of the stent.
-
11. The method of claim 2, wherein the stent is emersed for a period of time sufficient to permit a therapeutic agent to be absorbed into the porous cavities of the stent.
-
12. The method of claim 2, wherein the therapeutic agent is an anti-fibrin agent.
-
13. The method of claim 2, wherein the therapeutic agent is an antithrombin agent.
-
14. The method of claim 2, wherein the therapeutic agent is an anti-proliferative agent.
-
15. The method of claim 2, wherein the therapeutic agent is an anti-coagulant.
-
16. The method of claim 2, wherein the therapeutic agent is a GPII6IIIa blocker.
-
17. The method of claim 2, wherein the therapeutic agent is selected from the group consisting of forskolin, aspirin, dipyridamole, coumadin, ticlopodine, and heparin.
-
18. The method of claim 2, wherein the therapeutic agent is a vaso-active drug.
-
19. The method of claim 2, wherein the therapeutic agent is an anti-inflammatory agent.
-
20. The method of claim 2, wherein the therapeutic agent promotes endothelialization.
-
21. The method of claim 2, further comprising coating the stent with a polymer.
-
22. The method of claim 21, wherein the coating step occurs after the loading step.
-
23. The method of claim 21, wherein the polymer is configured to release the therapeutic agent at a substantially constant rate.
-
24. The method of claim 21, wherein the polymer is a biopolymer.
-
25. The method of claim 21, wherein the polymer is a poly lactic acid or fibrin.
-
26. The method of claim 25, wherein the polymer is selected from the group consisting of polyurethane, polyethylene teraphthalate tetrafluoride, polyethylene, polyethylene oxide (PEO) and silicone.
-
27. The method of claim 21, wherein the polymer is a synthetic polymer.
-
28. The method of claim 27, wherein the polymer is a hydrogel.
-
29. The method of claim 21, wherein the polymer is a heparin coating.
-
30. The method of claim 21, wherein the polymer is mixed with the therapeutic agent.
-
31. The method of claim 21, wherein the polymer is degradable.
-
32. The method of claim 1, wherein the cavities are open on their respective one ends and the sintered stent material forms closure walls on the respective opposite ends.
-
33. The method of claim 1, wherein said sintered stent material forms respective cavity side walls to define the respective holding cavities, and such side walls cause such cavities to cooperate with the loaded therapeutic agent in providing surface tension for holding the therapeutic agent in the respective cavities.
-
34. The method of claim 1, wherein said sintered stent material comprises a plurality of layers with at least one layer configured with the cavities opening outwardly to the one side and second layer forming a closure wall closing the respective cavities from opening to the opposite side.
-
35. The method of claim 1, wherein said sintered stent material comprises a pair of coextensive outer layers formed with the cavities facing outwardly in opposite directions and an intermediate layer sandwiched between the outer layers.
-
36. The method of claim 1, wherein the cavities are of substantially uniform size.
-
37. The method of claim 1, wherein the cavities are of substantially irregular size.
-
38. The method of claim 1, wherein said sintered stent material comprises a single layer.
Specification